Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
1.380
+0.030 (2.22%)
At close: Jan 22, 2026, 4:00 PM EST
1.370
-0.010 (-0.72%)
After-hours: Jan 22, 2026, 7:24 PM EST
Cyclerion Therapeutics Revenue
Cyclerion Therapeutics had revenue of $875.00K in the quarter ending September 30, 2025, with 351.03% growth. This brings the company's revenue in the last twelve months to $2.86M, up 1,371.65% year-over-year. In the year 2024, Cyclerion Therapeutics had annual revenue of $2.00M.
Revenue (ttm)
$2.86M
Revenue Growth
+1,371.65%
P/S Ratio
1.35
Revenue / Employee
$2,855,000
Employees
1
Market Cap
5.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 297.00K | -3.65M | -92.47% |
| Dec 31, 2021 | 3.94M | 1.65M | 71.69% |
| Dec 31, 2020 | 2.30M | -2.21M | -49.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GeoVax Labs | 3.35M |
| Xenetic Biosciences | 2.86M |
| Can-Fite BioPharma | 560.00K |
| VivoSim Labs | 140.00K |
| Silo Pharma | 72.10K |
CYCN News
- 16 days ago - Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript - Seeking Alpha
- 17 days ago - Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewsWire
- 4 months ago - Cyclerion Therapeutics, Inc. - Pre Recorded Special Call - Seeking Alpha
- 4 months ago - Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company - GlobeNewsWire
- 1 year ago - Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewsWire
- 1 year ago - Regina Graul, Ph.D., Promoted to Chief Executive Officer - GlobeNewsWire
- 2 years ago - Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewsWire
- 2 years ago - Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewsWire